May 13, 2025 09:17 AM EDTUpdated 12:51 PM
Pharma

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Drew Armstrong

Executive Editor

To­day on Post Hoc Live, Drew Arm­strong talked with Nick Ship­ley, the for­mer top lob­by­ist for the biotech in­dus­try, to break down Pres­i­dent Trump’s “most …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Unit­ed­Health Group CEO An­drew Wit­ty steps down

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

HHS fo­cus­es on 'trans­paren­cy' in third-round IRA ne­go­ti­a­tion guid­ance

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

A service from the Financial Times